Depression, Anxiety and Sleep in Parkinson's Disease
ConditionParkinson's Disease
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age50+
SponsorSohag University
About this trial
This study aims to assess the prevalence and severity of depression, anxiety, and sleep disorders among patients with idiopathic Parkinson's disease. The study will evaluate the relationship between neuropsychiatric symptoms and disease characteristics in order to improve early recognition and patient quality of life.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients diagnosed with idiopathic Parkinson's disease according to the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's Disease (Postuma et al., 2015).
Age ≥ 50 years.
Ability to understand and respond to questionnaires and rating scales.
Ability and willingness to provide informed consent.
Disqualifiers
Patients with atypical parkinsonism.
Patients with a history of other major neurological disorders (e.g., stroke, Alzheimer's disease, multiple sclerosis).
Patients with severe cognitive impairment or dementia that prevents reliable completion of rating scales.
Patients with a current diagnosis of severe psychiatric disorders unrelated to 5-Parkinson's disease (e.g., schizophrenia, bipolar disorder).
Trial population
Adult patients aged 50 years and older with idiopathic Parkinson's disease attending the Neurology Outpatient Clinic and/or admitted to the Neurology Department of Sohag University Hospital. A total of 100 eligible patients will be recruited to assess depression, anxiety, and sleep disorders.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Assessment of Depression Severity in Patients with idiopathic Parkinson's Disease
Depression severity measured using the Hamilton Depression Rating Scale (HAM-D). Scores range from 0 to 52, with higher scores indicating more severe depression.
Time frame
Baseline assessment during study enrollment.2
Assessment of Anxiety Severity in Patients with idiopathic Parkinson's Disease
Anxiety severity measured using the Hamilton Anxiety Rating Scale (HAM-A). Scores range from 0 to 56, with higher scores indicating more severe anxiety.
Time frame
Baseline3
Assessment of Sleep Disturbance in Patients with idiopathic Parkinson's Disease
Sleep disturbance measured using the Parkinson's Disease Sleep Scale (PDSS). Higher scores indicate better sleep quality and fewer sleep-related symptoms.
Time frame
BaselineLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: